An interventional study of Supplementation with calcium + vitamin D daily. in Epilepsy, Pregnant Woman and Bone Health, sponsored by The Fourth Affiliated Hospital of Zhejiang University School of Medicine. Recruiting at 1 site in China. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-16.
Sponsored by The Fourth Affiliated Hospital of Zhejiang University School of Medicine · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 101 studies in Epilepsy with a site in China — 35 open to participants now, 41 under way, 5 of them phase 3. Epilepsy · China.
Among the 101 studies in Epilepsy with a site in China, this one is the 43rd largest by planned enrollment of the 64 interventional ones that give a count, is one of 9 that started in 2026, is one of 21 with no phase, reaches primary completion later than 40 of the 40 other live ones, and was the 96th registered.
1,850 studies on the registry are indexed under Epilepsy; 418 are open to participants now.
Browse Epilepsy studies →35 of the 101 studies in Epilepsy with a site in China are open now. Recruiting first, the newest first:
Boston Scientific Corporation · Sites in China
Ages 18–65
Shanghai UniXell Biotechnology Co., Ltd · Sites in China
Ages 18–75
Xuanwu Hospital, Beijing · Sites in China
Ages 18–60
Xijing Hospital · Sites in China
Ages 18–65
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 20–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 284 Epilepsy studies recruiting now, 113 (40%) set no upper age limit and 148 (52%) stop at 75 or younger; 138 take children under 18; 54 take healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
101 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 6 · Phase 3 23 · Phase 4 5
First in 2006; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 50 across 1,240 interventional studies indexed under Epilepsy.
Median enrollment 141 across the 64 interventional studies, 234 across the 37 observational. Of the 37 that completed or were terminated, 22 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 101 have an industry lead sponsor. The 10 most frequent:
The Fourth Affiliated Hospital of Zhejiang University School of Medicine is the lead sponsor of 100 studies on the registry; 85 are open to participants now.
The Fourth Affiliated Hospital of Zhejiang University School of Medicine has 1 study filed under Epilepsy — fewer than ten, so there is no comparison to draw.
14 of the studies in Epilepsy with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06660394Phase 3Longboard PharmaceuticalsA Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) | 2026-12-31 |
| NCT06908226Phase 3Longboard PharmaceuticalsA Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE) | 2027-11-11 |
| NCT07095933Xuanwu Hospital, BeijingThe Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy | 2026-12-01 |
| NCT03822741Children's Hospital of Fudan UniversityEtiology and Treatment of Neonatal Seizure | 2026-12-30 |
| NCT04917939Second Affiliated Hospital, School of Medicine, Zhejiang UniversityGene Expression Changes of Brain Tissue in Human Temporal Lobe Epilepsy With Hippocampal Sclerosis | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 101 studies in Epilepsy with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is aimed to evaluate the efficacy of bone health management in improving pregnancy outcomes among WWE, and establish evidence-based vitamin D supplementation strategies for childbearing-age WWE.
Epilepsy, a common neurological disorder, affects approximately over 70 million individuals worldwide and 0.5-1% of women of childbearing age. Management of women with epilepsy (WWE) during their pregnancy period presents significant challenges. Optimal bone metabolism management is an essential component of obstetric care. To evaluate the efficacy of bone health management in improving pregnancy outcomes among WWE, and establish evidence-based vitamin D supplementation strategies for childbearing-age WWE. Based on the vitamin D levels of pregnant women with epilepsy during the early stage of pregnancy, intervention measures were taken to supplement vitamin D. The bone metabolism indicators of the offspring were tested.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intervention for epilepsy patients
Drug: Supplementation with calcium + vitamin D daily.
Epilepsy patients receive normal follow-up without any intervention.
Test bone metabolism indicators at 10-14 weeks of pregnancy and intervene based on vitamin D levels. * For vitamin D levels \> 20 ng/ml: Supplementation with 725 mg of calcium + 500 IU of vitamin D daily. * For 10 ng/ml \< vitamin D levels ≤20 ng/ml: Supplementation with 725 mg of calcium + 900 IU of vitamin D daily. * For vitamin D levels ≤10 ng/ml: Supplementation with 725 mg of calcium + 1300 IU of vitamin D daily.
Bone metabolisms indicators in offspring
25-hydroxy Vitamin D (ng/ml),procollagen type 1 N-terminal propeptide (P1NP, ng/ml),osteocalcin (OC, ng/ml)
Time frame: Childbirth
Bone metabolisms indicators in offspring
Parathyroid hormone (PTH, ng/L)
Time frame: Childbirth
Bone metabolisms indicators in offspring
β-crosslaps (β-CTX, pg/ml)
Time frame: Childbirth
Bone metabolisms indicators in offspring
Body length(cm)
Time frame: Childbirth
Bone metabolisms indicators in offspring
Weight(g)
Time frame: Childbirth
Bone metabolisms indicators in offspring
Head circumference(cm)
Time frame: Childbirth
Live birth rate without major congenital malformations (MCMs)
Live Birth Definition: Delivery of a fetus showing any sign of life at ≥20 weeks of gestation (WHO criteria). Major Congenital Malformations (MCMs) definition: Structural or functional abnormalities present at birth (modified from EUROCAT criteria).
Time frame: The outcome will be assessed at two critical time points:At Birth (Day 0-7 Post-Delivery),Within 30 Days Postnatal
Maternal Bone metabolisms indicators
25-hydroxy Vitamin D (ng/ml),procollagen type 1 N-terminal propeptide (P1NP, ng/ml),osteocalcin (OC, ng/ml)
Time frame: 12, 24, and 36 weeks of pregnancy, the time during delivery
Maternal Bone metabolisms indicators
β-crosslaps (β-CTX, pg/ml)
Time frame: 12, 24, and 36 weeks of pregnancy, the time during delivery
Maternal Bone metabolisms indicators
Parathyroid hormone (PTH,ng/L)
Time frame: 12, 24, and 36 weeks of pregnancy, the time during delivery
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jun 2026; primary completion for Jan 2035, 103 months later.
Of 339 non-industry interventional studies with no phase under Epilepsy, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 77. This study's planned 103 months is above that.
Counting every sponsor, half of 360 studies reached it within 42 months; a quarter within 19 and three quarters within 77.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Fourth Affiliated Hospital of Zhejiang University School of Medicine →